Article Sidebar
Published:
Sep 6, 2024DOI:
10.4314/tjpr.v23i7.9Keywords:
Article Details
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.
Main Article Content
Efficacy of tenofovir dipivoxil plus entecavir in patients with HBeAg positive chronic hepatitis B
Abstract
Purpose: To investigate the efficacy of tenofovir disoproxil fumarate (TDF) plus entecavir in patients with HBeAg positive chronic hepatitis B.
Methods: A total of 124 patients with HBeAg-positive chronic hepatitis who were hospitalized at The First People's Hospital of Jiangxia District, Wuhan, China were chosen as the subjects. They were then randomized equally into study and control groups. Control group received entecavir (0.5 mg orally) while the study group administered TDF (300 mg orally) daily for 48 weeks. Efficacy, liver function, inflammatory factors, liver fibrosis, and adverse reactions between the two groups were evaluated.
Results: After 12 weeks of treatment, HBeAg and HBV DNA negative seroconversion rates were significantly higher in the study group compared to control group (p < 0.05). At 24 and 48 weeks after treatment, alanine transaminase (ALT) normalization rate, HBeAg and HBV DNA negative seroconversion rate were also significantly higher compared to control group. Levels of heat shock protein 47 (HSP47), endothelial nitric oxide synthase (eNOS), and major basic protein (MBP) were significantly lower in study group compared to control group. Levels of hyaluronan (HA), type IC collagen (IV-C), N-terminal propeptide of procollagen type III (PIIINP), and laminin (LN) were significantly lower in study group compared to control group (p < 0.05). There was no significant difference in incidence of adverse reactions between the two groups (p > 0 05).
Conclusion: The combination of ETV and TDF significantly inhibits hepatitis B virus replication, and reduces inflammatory reactions. Further studies to determine the mechanism of action of tenofovir and entecavir on hepatitis B virus would be required.
